Literature DB >> 19616492

Epitope-based vaccination against pneumonic tularemia.

Stephen H Gregory1, Stephanie Mott, Jennifer Phung, Jinhee Lee, Leonard Moise, Julie A McMurry, William Martin, Anne S De Groot.   

Abstract

Francisella tularensis, the etiological agent of tularemia, is one of the most infectious bacterial pathogens known. No vaccine is currently approved for public use. Previously, we identified epitopes recognized specifically by T cells obtained from individuals following infection with F. tularensis. Here, we report that a subunit vaccine constructed based upon these epitopes elicited protective immunity in "humanized" HLA class II (DRB1*0401) transgenic mice. Vaccinated mice challenged intratracheally with a lethal dose of F. tularensis (Live Vaccine Strain) exhibited a rapid increase in pro-inflammatory cytokine production and diminished number of organisms in the lungs, and a concurrent increased rate of survival. These results demonstrate the efficacy of an epitope-based tularemia vaccine and suggest that such an approach might be widely applicable to the development of vaccines specific for intracellular bacterial pathogens.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19616492      PMCID: PMC2772204          DOI: 10.1016/j.vaccine.2009.06.101

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  43 in total

1.  Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides.

Authors:  I Gursel; M Gursel; K J Ishii; D M Klinman
Journal:  J Immunol       Date:  2001-09-15       Impact factor: 5.422

2.  CpG oligodeoxynucleotides induce murine macrophages to up-regulate chemokine mRNA expression.

Authors:  S Takeshita; F Takeshita; D E Haddad; K J Ishii; D M Klinman
Journal:  Cell Immunol       Date:  2000-12-15       Impact factor: 4.868

3.  Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen.

Authors:  J Wayne Conlan; Hua Shen; Ann Webb; Malcolm B Perry
Journal:  Vaccine       Date:  2002-10-04       Impact factor: 3.641

4.  Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis.

Authors:  M Fulop; P Mastroeni; M Green; R W Titball
Journal:  Vaccine       Date:  2001-08-14       Impact factor: 3.641

5.  Eotaxin represents the principal eosinophil chemoattractant in a novel murine asthma model induced by house dust containing cockroach allergens.

Authors:  J Kim; A C Merry; J A Nemzek; G L Bolgos; J Siddiqui; D G Remick
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

Review 6.  Tularemia as a biological weapon: medical and public health management.

Authors:  D T Dennis; T V Inglesby; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; A M Friedlander; J Hauer; M Layton; S R Lillibridge; J E McDade; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; K Tonat
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

7.  An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Authors:  Chandra Shekhar Bakshi; Meenakshi Malik; Manish Mahawar; Girish S Kirimanjeswara; Karsten R O Hazlett; Lance E Palmer; Martha B Furie; Rajendra Singh; J Andres Melendez; Timothy J Sellati; Dennis W Metzger
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

8.  The membrane form of tumor necrosis factor is sufficient to mediate partial innate immunity to Francisella tularensis live vaccine strain.

Authors:  Siobhán C Cowley; Michael F Goldberg; J Anthony Ho; Karen L Elkins
Journal:  J Infect Dis       Date:  2008-07-15       Impact factor: 5.226

Review 9.  Interleukin-12 and the regulation of innate resistance and adaptive immunity.

Authors:  Giorgio Trinchieri
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

Review 10.  Comparing protein abundance and mRNA expression levels on a genomic scale.

Authors:  Dov Greenbaum; Christopher Colangelo; Kenneth Williams; Mark Gerstein
Journal:  Genome Biol       Date:  2003-08-29       Impact factor: 13.583

View more
  25 in total

1.  Harnessing the power of genomics and immunoinformatics to produce improved vaccines.

Authors:  Leonard Moise; Leslie Cousens; Joanna Fueyo; Anne S De Groot
Journal:  Expert Opin Drug Discov       Date:  2010-12-01       Impact factor: 6.098

2.  Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.

Authors:  Stephen H Gregory; Wilbur H Chen; Stephanie Mott; John E Palardy; Nicholas A Parejo; Sara Heninger; Christine A Anderson; Andrew W Artenstein; Steven M Opal; Alan S Cross
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

3.  Preclinical development of HIvax: Human survivin highly immunogenic vaccines.

Authors:  Peter R Hoffmann; Maddalena Panigada; Elisa Soprana; Frances Terry; Ivo Sah Bandar; Andrea Napolitano; Aaron H Rose; Fukun W Hoffmann; Lishomwa C Ndhlovu; Mahdi Belcaid; Lenny Moise; Anne S De Groot; Michele Carbone; Giovanni Gaudino; Takashi Matsui; Antonio Siccardi; Pietro Bertino
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.

Authors:  Katharina Richard; Barbara J Mann; Aiping Qin; Eileen M Barry; Robert K Ernst; Stefanie N Vogel
Journal:  Clin Vaccine Immunol       Date:  2017-03-06

5.  VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone.

Authors:  Leonard Moise; R Mark Buller; Jill Schriewer; Jinhee Lee; Sharon E Frey; David B Weiner; William Martin; Anne S De Groot
Journal:  Vaccine       Date:  2010-11-04       Impact factor: 3.641

6.  HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model.

Authors:  Steven F Moss; Leonard Moise; Dong Soo Lee; Woojin Kim; Songhua Zhang; Jinhee Lee; Arlin B Rogers; William Martin; Anne S De Groot
Journal:  Vaccine       Date:  2011-01-12       Impact factor: 3.641

7.  A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens.

Authors:  Michael D Valentino; C Siddiq Abdul-Alim; Zachary J Maben; Denise Skrombolas; Lucinda L Hensley; Thomas H Kawula; Michelle Dziejman; Edith M Lord; Jeffrey A Frelinger; John G Frelinger
Journal:  J Immunol Methods       Date:  2011-08-18       Impact factor: 2.303

8.  Exploring the immunome: A brave new world for human vaccine development.

Authors:  Anne S De Groot
Journal:  Hum Vaccin       Date:  2009-12-15

Review 9.  Technical transformation of biodefense vaccines.

Authors:  Shan Lu; Shixia Wang
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

10.  A vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II molecules.

Authors:  Susan Pereira Ribeiro; Daniela Santoro Rosa; Simone Gonçalves Fonseca; Eliane Conti Mairena; Edilberto Postól; Sergio Costa Oliveira; Luiza Guilherme; Jorge Kalil; Edecio Cunha-Neto
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.